Nuveen Asset Management, LLC Rallybio Corp Transaction History

Nuveen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.91 - $4.39 $5,252 - $12,072	2,750 Added 4.5%	63,849 $152,000
Q3 2023 Nov 14, 2023	SELL	$3.37 - $6.16 $2,500 - $4,570	-742 Reduced 1.2%	61,099 $205,000
Q2 2023 Aug 14, 2023	BUY	$4.31 - $8.89 $168,158 - $346,852	39,016 Added 170.94%	61,841 $350,000
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $1,966 - $6,256	421 Added 1.88%	22,825 $150,000
Q3 2022 Nov 14, 2022	SELL	$7.54 - $14.56 $27,905 - $53,886	-3,701 Reduced 14.18%	22,404 $324,000
Q2 2022 Aug 15, 2022	BUY	$6.26 - $13.65 $1,959 - $4,272	313 Added 1.21%	26,105 $197,000
Q1 2022 May 16, 2022	BUY	$6.91 - $15.04 $178,222 - $387,911	25,792 New	25,792 $199,000

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.2M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.